Novo Nordisk A/S (NYSE:NVO) Trading 2.6% Higher - What's Next?

Novo Nordisk A/S (NYSE:NVO - Get Free Report) shares shot up 2.6% during trading on Friday . The company traded as high as $75.16 and last traded at $74.56. 4,460,996 shares traded hands during mid-day trading, a decline of 35% from the average session volume of 6,863,901 shares. The stock had previously closed at $72.65.

Wall Street Analyst Weigh In

A number of research firms have recently commented on NVO. BNP Paribas began coverage on Novo Nordisk A/S in a research note on Tuesday, April 15th. They issued an "underperform" rating on the stock. Dbs Bank cut Novo Nordisk A/S to a "sell" rating in a report on Friday, April 25th. Morgan Stanley began coverage on Novo Nordisk A/S in a research report on Wednesday, February 12th. They set an "equal weight" rating on the stock. Guggenheim lowered Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday, April 17th. Finally, Wall Street Zen raised Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a research report on Friday, April 25th. Two analysts have rated the stock with a sell rating, five have issued a hold rating, four have assigned a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $128.00.

Novo Nordisk A/S Stock Up 2.8%

The company has a market capitalization of $335.22 billion, a price-to-earnings ratio of 22.71, a price-to-earnings-growth ratio of 0.90 and a beta of 0.66. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The business has a 50-day moving average price of $65.87 and a 200-day moving average price of $80.71.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, meeting the consensus estimate of $0.92. The firm had revenue of $11.87 billion for the quarter. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, equities analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Center for Financial Planning Inc. increased its position in Novo Nordisk A/S by 72.4% in the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock worth $25,000 after purchasing an additional 123 shares during the last quarter. Strategic Investment Solutions Inc. IL increased its position in Novo Nordisk A/S by 2,727.3% in the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock worth $27,000 after purchasing an additional 300 shares during the last quarter. Copeland Capital Management LLC increased its position in Novo Nordisk A/S by 184.8% in the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock worth $27,000 after purchasing an additional 255 shares during the last quarter. North Capital Inc. acquired a new position in Novo Nordisk A/S in the 1st quarter worth about $27,000. Finally, Park Square Financial Group LLC acquired a new position in Novo Nordisk A/S in the 4th quarter worth about $29,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.